Recursion focuses on diseases where there is a high unmet need – including aggressive cancers and rare diseases. The company is already seeing encouraging data for some of its clinical programs ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug ...

Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

Recursion Pharma has agreed to merge with rival AI-powered drug discovery firm Exscientia in an all-stock deal valued at $688 million ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

The Motley Fool has a disclosure policy. Why Recursion Pharmaceuticals Stock Caught a Cold This Week Person in a lab gazing into a microscope.© Getty Images ...

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (RXRX -3.49%) stock was shedding more than 17% of its value week-to-date as of Thursday night.